The European Society for Medical Oncology Asia Congress 2024 was held in Singapore from December 6 to 8, 2024. The conference unveiled several groundbreaking studies in the field of hepatobiliary and pancreatic tumors, covering clinical applications related to neoadjuvant and adjuvant therapies, translational treatments, later-line therapies, and tumor biomarkers. These studies provide new insights into the clinical diagnosis and treatment of hepatobiliary and pancreatic malignancies and drive the development of related fields. This article focuses on the key topics in hepatobiliary and pancreatic malignancies presented at the conference, aiming to interpret the latest advances in the field and explore the hot issues and future directions for development in this area.